Abstract The familial aggregation of breast cancer has been well-described with approximately 25 % of breast cancers attributable to inherited mutations in currently known breast cancer susceptibility genes. PALB2 c.3113G[ A (p.Trp1038*) is a protein-truncating mutation which has been associated with high estimated risk of breast cancer in Australian women (91 %; 95 % CI = 44-100) to age 70 years. This study screened for PALB2 c.3113G[A in germline DNA representing 871 unrelated individuals from ''high-risk'' breast and/or ovarian cancer families evaluated in the setting of a Familial Cancer Centre in Australia. The PALB2 c.3113G[A mutation was identified in eight of 871 probands (0.92 %) from these families. Median age of diagnosis was 42 years. Five of these eight women had contra-lateral breast cancers. Available data suggests that PALB2 c.3113G[A is a rare mutation with estimated breast cancer risks similar in magnitude to that associated with BRCA2 mutations. Although the proportion of high-risk women carrying this PALB2 mutation is low, research efforts should continue in order to effect its translation into clinical genetic testing practice. Breast cancer is a common disorder with a strong hereditary component resulting in at least a two-fold increase in risk of the disease for women with an affected first-degree relative [1] [2] [3] [4] [5] [6] [7] [8] . Approximately 20 % of women in the population are reported to have one or more first-degree relatives affected with breast cancer [9] . The familial aggregation of breast cancer is thought to be largely due to heritable factors [10] yet mutations in BRCA1 and BRCA2 account for only around 16 % of the genetic contribution to familial breast cancer [11, 12] . Recent studies have
investigated the possibility that rare germline mutations in additional genes explain the remaining familial risk. This has led to the description of a number of new breast cancer susceptibility genes including ATM [13] , CHEK2 [14] , BRIP1 [15] and PALB2 [16] .
Normal PALB2 function is essential for homologous recombination (HR) repair of DNA double strand breaks where the protein acts as a bridge, forming an integral link between BRCA1 and BRCA2 [17, 18] . Mono-allelic mutations in PALB2 have been estimated to confer an increased risk of breast cancer of two-to six-fold [16] but the statistical approach applied had some limitations [19] .
Modified segregation analysis involving breast cancer cases, unselected for family history and their first-and second-degree relatives estimated the penetrance of the PALB2 c.3113G[A mutation to age 70 years to be 91 %, albeit with wide confidence intervals (95 % confidence interval = 44-100) [20] . The confidence interval of the estimate encompasses and is, therefore, comparable to the average estimated risk for breast cancer for BRCA2 mutation carriers to the age of 71 [21] . However, the segregation pattern in some families cannot exclude the possibility of additional genetic breast cancer risk modifiers being present in these families.
The PALB2 c.3113G[A (p.Trp1038*) mutation appears to be a recurrent mutation associated with a high estimated risk of breast cancer. Hence, we aimed to establish the contribution of PALB2 c.3113G[A to breast cancer in the group of women assessed as 'high risk' on the basis of their personal and family history of breast and/or ovarian cancer following clinical assessment at a Familial Cancer Centre (FCC). To determine the prevalence of PALB2 c.3113G[A in this clinic-based population, targeted screening for this mutation was performed in unrelated probands from the Victorian Familial Breast Cancer Cohort (VFBCC) of ''high risk'' breast and/or ovarian cancer families [22] . The cohort includes individuals assessed by one of the three Familial Cancer Centers in Victoria, Australia (The Peter MacCallum Cancer Centre, The Royal Melbourne Hospital, and the Victorian Clinical Genetic Service) between 1997 and 2010. For all families, the cancer history was assessed through questionnaire and person consultation and was verified through local cancer registries or individual medical records. Initially, classification of a proband as 'high risk' was based on national guidelines requiring a family history involving a minimum of two, first-or second-degree relatives with breast cancer with at least one additional risk factor (additional affected close relatives, diagnosis before 40 years, multiple primary breast or ovarian cancers in one individual, male breast cancer, or Ashkenazi Jewish ancestry). From 2003, individuals were classified as 'high risk' where the proband was estimated to have a C10 % probability of a mutation in BRCA1 or BRCA2 by an established mutation prediction tool [23, 24] .
Diagnostic A total of 972 individuals were recruited by the VFBCC. Of these, 95 were excluded as (1) their DNA samples were found to be unsuitable for screening (n = 2), (2) they were identified as carriers of BRCA1, BRCA2, or TP53 mutations (n = 22), (3) they were not affected with breast cancer or that their cancer status could not be determined (n = 71) (4) or they failed genotyping (n = 6). (Fig. 1) . The remaining 871 individuals included 848 women and 23 men who were affected with breast and/or ovarian cancer. DNA extracted from peripheral blood of the participants was whole genome amplified (WGA) using the Repli-G Phi-mediated amplification system (Qiagen, Hilden, Germany) and analysed for PALB2 c.3113G[A using the Custom Taqman Ò SNP Genotyping Assay (Life Technologies, Carlsbad, California, USA). The Taqman Ò probe-based assays were performed as per manufacturer's instructions on the LightCycler480 (Roche Applied Science, Penzberg, Upper Bavaria, Germany). Non-WGA DNA samples were used to confirm positive results of the Taqman Ò probe-based assay by Sanger sequencing. DNA samples from six individuals (0.6 %) failed the Taqman Ò probe-based assays. Of the 871 unrelated participants who were successfully genotyped for PALB2 c.3113G[A, eight women (0.92 %) were identified as carriers. The median age of onset of the eight mutation carriers was 42 (33-49) years compared to a median age of onset of 45 (20-84) years in non-carriers (p = 0.07). (Table 1) .
Information on the segregation of the PALB2 c.3113G[A mutation in the families of the carriers was limited, as blood samples of the relatives were typically not available. However, one female sibling of an affected PALB2 c.3113G[A carrier (Fig. 2h) , diagnosed with a grade 2 infiltrating ductal carcinoma (ER?/PR?/HER2?) at the age of 36 years was also a participant in the VFBCC; genotyping confirmed that she also carried the PALB2 c.3113G[A mutation. Figure 2 shows the pedigrees of the carriers of PALB2 c.3113G[A. Five of the eight carriers had two primary diagnoses of breast cancer. The median age of onset for the second diagnoses of these five unrelated participants was 51 (range, 38-58). Five of the nine PALB2 c.3113G[A carriers were affected by contra-lateral breast cancer (63 %) compared to 123/740 (17 %) (p = 0.009, Fisher's exact test) of the non-carrier women with breast cancer. This finding supports the association with contra-lateral breast cancer that has been reported previously [25] .
There were a total of 14 breast cancer diagnoses among the nine PALB2 mutation carriers who had personal diagnoses of breast cancer. Pathology reports were available for 11 of the 14 cancers; ten cases were infiltrating ductal carcinomas and one an infiltrating lobular carcinoma (Table 2) . Information on histological grade and receptor status was either unavailable or incomplete on three of the pathology reports. For the remaining eight tumours, seven of the cancers were either histological grade 2 or 3 using the modified Bloom-Richardson system [26] , and two of the nine were triple negative, i.e. negative for estrogen and progesterone receptors (ER and PR), and human epidermal growth factor receptor 2 (HER2) expression (Table 2) .
Our study demonstrates that the PALB2 c.3113G[A mutation contributes to the risk of breast cancer in approximately 1 % of the high-risk breast and/or ovarian cancer families presenting to FCCs in Victoria, Australia. The mutation was found at a similar level in two other studies that involved breast and/or ovarian cancer multiplecase families attending clinical genetics services in Australia and/or New Zealand [20, 27] . Table 3 compares the carrier frequency of PALB2 c.3113G[A observed in this study with the four previous studies. [20] The prevalence of PALB2 c.3113G[A observed in Victorian FCCs, together with its high estimated breast cancer risk [20] that is similar, on average, to that conferred by BRCA2 mutations [21] , supports the progress of PALB2 c.3113G[A into a clinical translation phase. Nonetheless, the translation of PALB2 genetic testing into routine clinical practice will be complex as the value of a negative presymptomatic test for family members is not always clear. This is a challenging and dynamic phase that requires further studies to exclude the presence of other Women with breast or ovarian cancer (68 breast cancer and two ovarian cancer cases). These cases had an early age at diagnosis (under the age of 50 years or pre-menopausal), a strong family history of breast and ovarian cancers in first-or second-degree relatives and were previously screened for mutations in BRCA1 and BRCA2 and were found to be non-carriers.
New South Wales, Australia 1/70 (1.4 %) a Casadei et al. [28] Study cohort consisted of breast cancer cases with at least two first-or second-degree relative with breast cancer. The breast cancer cases were screened for and not found to be carriers of BRCA1 or BRCA2 mutations. 172 breast cancer cases of the study cohort (all females) were of the Ashkenazi Jewish ancestry and 972 (959 females and 13 males) were of other unselected ancestries. 
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